Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Delayed Hong Kong S.E.
Other stock markets
 11:08:27 2024-04-29 pm EDT 		5-day change 1st Jan Change
12.28 HKD -0.81% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +4.42% -27.76%
Apr. 29 Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator
Yuyuan Tourist Mart CFO Steps Down
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets
Fosun Pharma Board Approves Unlocking, Vesting of Shares
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Other languages